


# Results Fiscal Year 2011/12

Investor Call  
Mannheim, 14<sup>th</sup> May 2012



Reimund Pohl / Dr. Michael Majerus  
CEO / CFO



# Disclaimer

© 2012 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the “Company” and, together with its subsidiaries and affiliates, “PHOENIX”) solely in connection with the release of the results of the fiscal year 2011/12 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the “Parties”) as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words “targets,” “believes,” “expects,” “aims,” “intends,” “may,” “anticipates,” “would,” “could” or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.

## Highlights of the Fiscal Year 2011/12




Reimund Pohl  
CEO

## Group Financials Fiscal Year 2011/12




Dr. Michael Majerus  
CFO

## Questions & Answers




PHOENIX's development during business year 2011/12 was positive

- Stable development of net turnover
- Significant improvement in profit after tax
- Optimized and solid financial structure
- Further reduction of the group's indebtedness
- Strengthened balance sheet




PHOENIX did well in a challenging and difficult market environment




PHOENIX was able to set itself apart from the general trend of the sector

# Despite increasing market pressure, PHOENIX shows a stable revenue and growth in gross profit

## Revenue



## Gross Profit




- PHOENIX shows a **stable revenue development** – once more, PHOENIX group confirmed its position as leading pharmaceutical distributor in Europe
- **Gross profit and gross margin improved** as a result of the margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business, especially through the inclusion of the Lloyds pharmacies in the Netherlands

(mEUR)


# Year-over-year development of profit for the period confirms the group's solid position

## EBITDA



## Profit for the period

(after tax, before minorities)



- The **EBITDA** decrease is mainly influenced by a positive one-time effect from the reduction of pension obligations in the previous year (+19,2 mEUR in 2010/11) as well as increased personnel cost and other cost in 2011/12, mainly due to first time full consolidation of the JV in the Netherlands and acquisitions in Italy
- **Profit for the period** is driven by the further improvement in the financial result, mainly due to the reduced debt level and the better financing conditions, as well as improved tax ratio

(mEUR)

\* Prior-year figures were restated due to first-time adoption of IAS 19.93A

# Wholesale market: PHOENIX has a diversified country portfolio with top market positions

- ✓ About 150 wholesale and pre-wholesale sites in 23 countries across Europe
- ✓ European market leader
- ✓ Best-in-class market coverage in Eastern Europe
- ✓ PHOENIX with #1 market positions in 11 countries (Germany, Italy, Czech Republic, Hungary, Slovakia, Serbia, Bosnia, Bulgaria, Denmark, Finland and Sweden)



	Austria
	Bosnia
	Bulgaria
	Switzerland
	Czech Republic
	Germany
	Denmark
	Estonia
	Finland
	France
	Croatia
	Hungary
	Italy
	Lithuania
	Latvia
	Macedonia
	The Netherlands
	Norway
	Poland
	Serbia
	Sweden
	Slovakia
	United Kingdom

■ PHOENIX with #1 market position  
■ PHOENIX with #2 or #3 market position  
■ PHOENIX with lower market position

# Retail market: PHOENIX optimizes its pharmacy portfolio through selected M&A transactions

	Austria
	Bosnia
	Bulgaria
	Switzerland
	Czech Republic
	Germany
	Denmark
	Estonia
	Finland
	France
	Croatia
	Hungary
	Italy
	Lithuania
	Latvia
	Macedonia
	The Netherlands
	Norway
	Poland
	Serbia
	Sweden
	Slovakia
	United Kingdom



- ✓ As per January 31, 2012, PHOENIX operates 1,547 pharmacies in 13 countries; this number includes a total of 4 pharmacies held for sale in Slovakia
- ✓ Outside UK, PHOENIX group has the largest number of pharmacies within Europe
- ✓ As planned, PHOENIX successfully sold its unprofitable minor retail activities in Sweden (2010) as well as in Croatia (2011)
- ✓ Also in 2010, PHOENIX and Celesio joined forces in the Netherlands in order to optimize the market position



# The country portfolio of PHOENIX group opens growth opportunities and allows to mitigate risks



## Germany

- Number 1 market position in wholesale
- 21 sales & distribution centres

## Western Europe


- 780 pharmacies
- 73 sales & distribution centres

## Northern Europe


- 533 pharmacies
- 19 sales & distribution centres

## Eastern Europe


- 234 pharmacies
- 33 sales & distribution centres



Revenue split



Currency split




# Balancing effect of the country portfolio: Development of total income by group and selected countries



## Total Income

(mEUR)



Different scales are used in order to be able to show PHOENIX group and selected countries in one single graph

Accounting according to German GAAP until FY 2007/08; starting from FY 2008/09 according to IFRS

Results of the Fiscal Year 2011/12  
PHOENIX group, 05/14/2012, Mannheim, Germany

## Business year 2011/12

### Legislation/regulation:

- Interim period January – December 2011
  - Continuation of the existing wholesalers' remuneration scheme
  - An overall wholesale rebate of 0.85% on all prescription drugs was imposed
- **On the level of the pharmaceutical wholesalers in Germany, a total savings effect of 200 mEUR was to be realized** (following the regulation motivation)

### Actions and effects with PHOENIX:

- PHOENIX strived to counterbalance the negative effects resulting from the imposed savings through various measures in the field of sales and operations
- In the business year 2011/12, PHOENIX was partially successful in doing so
- During 2011/12, PHOENIX has worked on a new condition system for 2012 and communicated the new systems into the German market as the first player

## Business year 2012/13

### Legislation/regulation:

- New margin scheme starting January 2012
  - Flat margin (3.15%), in addition fixed remuneration component of 0.70 EUR per package
  - Total remuneration capped at 38.50 EUR
- **“Continuation” of the savings effect from the prior year by use of a different margin scheme/structure**

### Actions and effects with PHOENIX:

- The necessary change in the condition system imposed by the AMNOG legislation was diligently prepared by PHOENIX: All customers have been informed before January 2012
- Since the beginning of 2012, the German pharmaceutical wholesale market has become highly competitive
- Per se, the changeover towards the new margin scheme is positive for PHOENIX and for the pharmaceutical wholesale sector

PHOENIX is well-positioned for the future; this has recently been confirmed by two rating agencies

## STANDARD & POOR'S

## Fitch Ratings

### Standard & Poor's

- On 07 February 2012, the rating agency Standard & Poor's upgraded the **company's rating** from BB-/positive to **BB/stable**
- At the same time, the **bond rating** was improved from B to **B+**

### Fitch Ratings

- On 17 October 2011, the rating agency Fitch published a first **company rating of BB with stable outlook**
- At the same time, a **bond rating** was published with **B+**

## Highlights of the Fiscal Year 2011/12



Reimund Pohl  
CEO

## Group Financials Fiscal Year 2011/12



Dr. Michael Majerus  
CFO

## Questions & Answers

Despite the challenging market environment, the P&L shows stable net turnover and significant improvements within the financial result and the tax rate

Profit & Loss (in mEUR)	FY* 2010/11	FY 2011/12	Share of net turnover	Delta in %
<b>Net turnover</b>	<b>21,738</b>	<b>21,661</b>	<b>100%</b>	<b>-0.4%</b>
Cost of goods sold	-19,793	-19,657	-90.8%	-0.7%
<b>Gross profit</b>	<b>1,945</b>	<b>2,003</b>	<b>9.2%</b>	<b>3.0%</b>
Other income	147	147	0.7%	-0.3%
Personnel expenses	-934	-1,018	-4.7%	9.0%
Other operative expenses	-589	-597	-2.8%	1.3%
Result from associates and other invest.	8	4	0.0%	-53.5%
<b>EBITDA</b>	<b>577</b>	<b>539</b>	<b>2.5%</b>	<b>-6.5%</b>
Depreciation	-90	-101	-0.5%	12.7%
Financial result	-212	-137	-0.6%	-35.4%
<b>Profit before taxes</b>	<b>275</b>	<b>301</b>	<b>1.4%</b>	<b>9.5%</b>
Income taxes total	-126	-59	-0.3%	-53.1%
<b>Profit for the period</b>	<b>149</b>	<b>242</b>	<b>1.1%</b>	<b>62.8%</b>

## Developments

- **Stable development of net turnover** despite regulatory impacts
- **Gross profit** improved as a result of margin-oriented sales policy, additional higher-margin revenue, and the increasing share of retail business
- Gross profit improvement does not allow to fully compensate increased operative expenses: **personnel expenses** and **other operative expenses** increased due to first time consolidation of joint venture in the Netherlands, acquisitions in Italy, and normal wage as well as transport cost increase
- As PHOENIX group reduced net debt, optimized its financing conditions, and is no longer burdened with restructuring costs, the **financial result** and in consequence the profit before tax are significantly improved
- Improving its effective **tax rate**, PHOENIX is able to reduce tax level despite higher profit before tax
- **Profit for the period** is significantly improved

\* Prior-year figures were restated due to first-time adoption of IAS 19.93A as well as changes in the presentation within the financial result

# PHOENIX group's optimized financial structure improves the financial result substantially




Financial result (in mEUR)	FY 2010/11	FY 2011/12	Delta
Interest income	46	34	-12
Interest expenses	-201	-174	27
<b>Interest result</b>	<b>-155</b>	<b>-140</b>	<b>15</b>
Other net financial result*	-86	2	87
<b>Financial result excl. gains from financial asset disposal</b>	<b>-240</b>	<b>-138</b>	<b>102</b>
Gains from the disposal of financial assets	28	1	-27
<b>Financial result incl. gains from financial asset disposal</b>	<b>-212</b>	<b>-137</b>	<b>75</b>

Developments
<ul style="list-style-type: none"> <li>▪ Reduction of interest income due to repayment of granted VEM loan in BY 2010/2011</li> <li>▪ Lower interest expenses are mainly driven by reduced debt and optimized interest rates</li> <li>▪ Other net financial result profits from end of restructuring costs</li> </ul>

\* Other net financial result comprises

- “other financial income and expenses“,
- “financial income and expenses from derivatives” as well as
- “exchange rate gains and losses” related to the financial result

# PHOENIX continues its committed path of strengthening its balance sheet



### Developments

- Positive cash flow resulted in reduced financial liabilities
- Equity ratio further improved by profit of the period and reduced balance sheet total, due to reduced financial liabilities
- Slight grow in inventories in order to provide optimized delivery capabilities in Germany as well as higher purchasing volumes in Italy in order to profit from supplier rebates
- Despite absolute increase of Net Working Capital, on average NWC days still lower than previous year
  - NWC days 2010/11: 42.1
  - NWC days 2011/12: 39.9


- Financial Liabilities
- Cash & Equivalents
- Equity
- Net Working Capital
- Other

\* Prior-year figures were restated due to first-time adoption of IAS 19.93A and other reclassifications



# Net Debt is significantly improved compared to previous year


01/31/2012



## Y-o-Y developments

- Net Debt reduction of 321 mEUR compared to FY 2010/11:
  - 209 mEUR from reduced net financial liabilities (prepayments of SFA)
  - 110 mEUR from reduced ABS/factoring

01/31/2011




(mEUR)

# Solid financial structure after refinancing provides meaningful financial flexibility


## Financial facilities and headroom

01/31/2012



- Diversified financing structure
- Significant financial headroom and efficient utilisation of cash allowed slight reduction of credit lines


## Debt maturity profile



- Since end of last financial year PHOENIX extended maturities for 0.6 bnEUR until end of 2015
- With the extension of maturities beyond the maturity of the high yield bond, banks signal their confidence in PHOENIX's credit worthiness

(mEUR)


# The active management of net working capital shows significant improvements



<b>Key Achievements</b>	<ul style="list-style-type: none"> <li>▪ Slight increase in stock (optimized delivery cap. in Germany and profit from supplier rebates in Italy)</li> <li>▪ Due to successful local optimization, receivables and DSO improved</li> <li>▪ Payables significantly improved</li> <li>▪ Overall, significantly improved NWC</li> </ul>
-------------------------	---

• Balance sheet figures as externally reported  
 • Net working capital days: Average figures for the respective period; figures including ABS/factoring; may include rounding differences

# The cash flow for fiscal year shows a positive free cash flow – previous year with major one-off effects

















## Cash flow development

- Improved profit of the period due to better financial results and low tax rate
- Second column reduced by lower level of non-paid interest and non-paid taxes
- Major potential within working capital leveraged in previous year (effect not repeatable), but maintenance of optimized net working capital days
- Cash flow from investing activities in 2010/11 is influenced by exceptional items (especially payback of granted loan in the amount of 459 mEUR and divestments of financial assets)

(mEUR)

\* Prior-year figures were restated due to first-time adoption of IAS 19.93A as well as changes in the presentation within the financial result


# Summary: Development of key credit indicators

	01/31/2011*	01/31/2012	Delta in %	
Equity (in mEUR)	1,772.4	1,935.6	9.2%	
Equity Ratio	23.4%	26.1%	11.7%	
Net Debt (in mEUR)	2,176.6	1,855.7	-14.7%	
Gearing (Net debt/Equity)	122.8%	95.9%	-21.9%	
	FY 2010/11*	FY 2011/12	Delta in %	
EBITDA (in mEUR)	576.9	539.4	-6.5%	
EBITDA-Margin	2.7%	2.5%	-6.2%	
Adjusted EBITDA** (in mEUR)	614.0	566.5	-7.7%	
Adj.-EBITDA-Margin**	2.8%	2.6%	-7.1%	
Net Debt / Adjusted EBITDA**	3.54	3.28	-7.3%	
Interest Coverage Ratio (EBIT / Interest Expenses)	2.4	2.5	3.9%	
Profit before tax (in mEUR)	274.9	300.9	9.5%	
PBT-Margin	1.3%	1.4%	9.8%	
Profit after tax (in mEUR)	148.6	241.7	62.7%	
PAT-Margin	0.7%	1.1%	63.3%	


\* Prior-year figures were restated due to first-time adoption of IAS 19.93A as well as changes in the presentation within the financial result.

\*\* Adjusted EBITDA according to Bond definition

After decrease in fall 2011, the price of the PHOENIX bond is now back at approx. 110% of the nominal value



# The good performance of the PHOENIX bond starting Oct'11 is shown by the spread to the high yield index



\* Yield to maturity minus swap rate

# PHOENIX group with unchanged stringent financial policy

## Deleveraging strategy


- Further deleveraging is integral part of PHOENIX's financial policy and is backed by its main shareholders
- Net Debt/EBITDA target of around 3.0x
- PHOENIX is confident to reach its leverage target in the next two years

## Carefully managed acquisition activity

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions (mainly pharmacies) may also be pursued, but only within a predefined acquisition budget



Reporting Event	Date
1 <sup>st</sup> Quarter - Results	06/27/2012
1 <sup>st</sup> Half Year - Results	09/27/2012
3 <sup>rd</sup> Quarter - Results	12/20/2012



**PHOENIX** group